New scientific publication focuses on DiviTum® and highlights the need for biomarkers of CDK4/6 inhibitors
The authors depicture the biological drivers behind CDK4/6 resistance, succeeded by how DiviTumÒ can contribute to identifying patients where an early switch to an alternative treatment can improve patient outcome and support treatment decisions.
DiviTum® has in several studies proven the ability to evaluate CDK4/6 treatment responses in women with breast cancer, endorsing the potential of the assay to evaluate the effects of a targeted breast cancer therapy. The CDK 4/6 inhibitors sales is in excess of 4 billion USD/year and presently no biomarkers are clinically in routine use to evaluate or monitor the efficacy of this class of drugs.
“It’s encouraging that a key application for DiviTum® is given attention in this scientific article, summarizing the evidence so far. For patients with metastatic breast cancer, the published results support that DiviTum® can be used to evaluate the treatment efficacy of CDK 4/6 inhibitors. We aim to supply DiviTum® as a tool that can contribute to improved outcome for patients,” says Anders Rylander, CEO, Biovica.